Azra H Ligon

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11368648/publications.pdf

Version: 2024-02-01

97	20,670	34076 52	42364 92
papers	citations	h-index	g-index

97	97	97	29340
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A molecularly integrated grade for meningioma. Neuro-Oncology, 2022, 24, 796-808.	0.6	83
2	The relationship between performance on the medical genetics and genomics in-training and certifying examinations. Genetics in Medicine, 2022, 24, 225-231.	1.1	1
3	Molecular and Clinical Characterization of Radiation-Induced Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, .	0.4	0
4	Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. Neuro-Oncology, 2022, 24, 1404-1404.	0.6	5
5	LGG-06. Selumetinib in pediatric patients with non-neurofibromatosis type 1-associated, non-optic pathway (OPG) and non-pilocytic recurrent/progressive low-grade glioma harboring BRAFV600E mutation or BRAF-KIAA1549 fusion: a multicenter prospective Pediatric Brain Tumor Consortium (PBTC) Phase 2 trial. Neuro-Oncology, 2022, 24, i88-i88.	0.6	3
6	Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays. Modern Pathology, 2021, 34, 603-612.	2.9	15
7	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood, 2021, 137, 1353-1364.	0.6	31
8	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clinical Cancer Research, 2021, 27, 1695-1705.	3.2	19
9	A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro-Oncology, 2021, 23, 1777-1788.	0.6	68
10	Characterization of molecular signatures of supratentorial ependymomas. Modern Pathology, 2020, 33, 47-56.	2.9	10
11	Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathologica Communications, 2020, 8, 107.	2.4	84
12	A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. American Journal of Surgical Pathology, 2020, 44, 922-933.	2.1	131
13	Copy number assessment in the genomic analysis of CNS neoplasia: An evidence-based review from the cancer genomics consortium (CGC) working group on primary CNS tumors. Cancer Genetics, 2020, 243, 19-47.	0.2	3
14	Mechanisms and therapeutic implications of hypermutation in gliomas. Nature, 2020, 580, 517-523.	13.7	374
15	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Journal of Clinical Oncology, 2019, 37, 3291-3299.	0.8	195
16	Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma. American Journal of Clinical Pathology, 2019, 152, 97-108.	0.4	36
17	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncology, The, 2019, 20, 1011-1022.	5.1	315
18	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. Journal of Clinical Oncology, 2019, 37, 1997-2007.	0.8	170

#	Article	IF	Citations
19	LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY, PBTC-029B. Neuro-Oncology, 2019, 21, ii98-ii99.	0.6	3
20	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of Clinical Oncology, 2019, 37, 741-750.	0.8	103
21	Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Journal of Clinical Oncology, 2019, 37, 481-489.	0.8	265
22	Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. Cureus, 2019, 11, e4726.	0.2	2
23	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 942-950.	0.8	273
24	LTBK-01. UPDATES ON THE PHASE II AND RE-TREATMENT STUDY OF AZD6244 (SELUMETINIB) FOR CHILDREN WITH RECURRENT OR REFRACTORY PEDIATRIC LOW GRADE GLIOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY. Neuro-Oncology, 2018, 20, i214-i214.	0.6	4
25	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. Blood, 2018, 132, 228-228.	0.6	14
26	Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma. Blood, 2018, 132, 1579-1579.	0.6	2
27	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology, 2017, 19, now235.	0.6	99
28	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro-Oncology, 2017, 19, now294.	0.6	54
29	Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. Archives of Pathology and Laboratory Medicine, 2017, 141, 751-758.	1.2	350
30	Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro-Oncology, 2017, 19, 908-917.	0.6	23
31	From Prognostication to Personalized Medicine: Classification of Tumors of the Central Nervous System (CNS) Using Chromosomal Microarrays. Current Genetic Medicine Reports, 2017, 5, 117-124.	1.9	2
32	Landscape of Genomic Alterations in Pituitary Adenomas. Clinical Cancer Research, 2017, 23, 1841-1851.	3.2	94
33	A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study.. Journal of Clinical Oncology, 2017, 35, 10504-10504.	0.8	11
34	Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight, 2016, 1, e87062.	2.3	340
35	Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagnostic Pathology, 2016, 11, 13.	0.9	10
36	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Journal of Clinical Oncology, 2016, 34, 2690-2697.	0.8	634

#	Article	IF	Citations
37	Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood, 2016, 127, 869-881.	0.6	429
38	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncology, The, 2016, 17, 1283-1294.	5.1	818
39	Genomic characterization of recurrent high-grade astroblastoma. Cancer Genetics, 2016, 209, 321-330.	0.2	17
40	Classical Hodgkin Lymphoma with Reduced Î²2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunology Research, 2016, 4, 910-916.	1.6	146
41	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Journal of Clinical Oncology, 2016, 34, 2698-2704.	0.8	868
42	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nature Medicine, 2016, 22, 723-726.	15.2	105
43	Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation. World Neurosurgery, 2016, 85, 96-105.	0.7	14
44	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	9.4	214
45	Oncogenic PI3K mutations are as common asAKT1andSMOmutations in meningioma. Neuro-Oncology, 2016, 18, 649-655.	0.6	221
46	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncology, 2016, 2, 518.	3.4	121
47	A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro-Oncology, 2016, 18, 269-274.	0.6	64
48	Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clinical Cancer Research, 2016, 22, 1185-1196.	3.2	89
49	Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). Blood, 2016, 128, 2923-2923.	0.6	5
50	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro-Oncology, 2015, 17, 1486-1496.	0.6	39
51	ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genetics, 2015, 208, 345-350.	0.2	73
52	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro-Oncology, 2015, 17, 1344-1355.	0.6	40
53	PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. New England Journal of Medicine, 2015, 372, 311-319.	13.9	3,099
54	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Blood, 2015, 126, 176-176.	0.6	4

#	Article	IF	Citations
55	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget, 2014, 5, 10596-10606.	0.8	65
56	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. Clinical Cancer Research, 2014, 20, 1873-1883.	3.2	63
57	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genetics, 2014, 46, 462-466.	9.4	381
58	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology, 2014, 16, 567-578.	0.6	140
59	EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing. Cancer Discovery, 2014, 4, 956-971.	7.7	251
60	Optic Nerve Glioma. Ophthalmic Plastic and Reconstructive Surgery, 2014, 30, 372-376.	0.4	8
61	Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study. Blood, 2014, 124, 289-289.	0.6	10
62	Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies. Blood, 2014, 124, 291-291.	0.6	92
63	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget, 2014, 5, 8083-8092.	0.8	55
64	Complex cytogenetic rearrangements at the DURS 1 locus in syndromic Duane retraction syndrome. Clinical Case Reports (discontinued), 2013, 1, 30-37.	0.2	3
65	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8188-8193.	3.3	188
66	BRAFDuplications and MAPK Pathway Activation Are Frequent in Gliomas of the Optic Nerve Proper. Journal of Neuropathology and Experimental Neurology, 2012, 71, 789-795.	0.9	59
67	DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues. PLoS ONE, 2012, 7, e38881.	1.1	28
68	Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pediatric Low-Grade Gliomas. Journal of Molecular Diagnostics, 2011, 13, 669-677.	1.2	81
69	Reporting of Diagnostic Cytogenetic Results. Current Protocols in Human Genetics, 2011, 70, 1D.	3.5	0
70	BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications. PLoS ONE, 2011, 6, e17948.	1.1	268
71	Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nature Genetics, 2011, 43, 869-874.	9.4	945
72	Reporting of Diagnostic Cytogenetic Results. Current Protocols in Human Genetics, 2010, 67, 1D.1-23.	3.5	0

#	Article	IF	Citations
73	The landscape of somatic copy-number alteration across human cancers. Nature, 2010, 463, 899-905.	13.7	3,331
74	Overexpression of Elafin in Ovarian Carcinoma Is Driven by Genomic Gains and Activation of the Nuclear Factor Î¹B Pathway and Is Associated with Poor Overall Survival. Neoplasia, 2010, 12, 161-IN15.	2.3	56
75	Establishment and Genomic Characterization of Mouse Xenografts of Human Primary Prostate Tumors. American Journal of Pathology, 2010, 176, 1901-1913.	1.9	59
76	Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors. Journal of Clinical Oncology, 2010, 28, 835-840.	0.8	362
77	Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss. Clinical Cancer Research, 2009, 15, 6430-6437.	3.2	88
78	Characterization of Apparently Balanced Chromosomal Rearrangements from the Developmental Genome Anatomy Project. American Journal of Human Genetics, 2008, 82, 712-722.	2.6	95
79	CDK8 is a colorectal cancer oncogene that regulates Î²-catenin activity. Nature, 2008, 455, 547-551.	13.7	594
80	NFIA Haploinsufficiency Is Associated with a CNS Malformation Syndrome and Urinary Tract Defects. PLoS Genetics, 2007, 3, e80.	1.5	100
81	Disruption of Diacylglycerol Kinase Delta (DGKD) Associated with Seizures in Humans and Mice. American Journal of Human Genetics, 2007, 80, 792-799.	2.6	39
82	Candidate loci for Zimmermannâ€“Laband syndrome at 3p14.3. American Journal of Medical Genetics, Part A, 2007, 143A, 107-111.	0.7	17
83	Disruption of a synaptotagmin (SYT14) associated with neurodevelopmental abnormalities. American Journal of Medical Genetics, Part A, 2007, 143A, 558-563.	0.7	14
84	Constitutional Rearrangement of the Architectural Factor HMGA2: A Novel Human Phenotype Including Overgrowth and Lipomas. American Journal of Human Genetics, 2005, 76, 340-348.	2.6	116
85	Reporting of Diagnostic Cytogenetic Results. Current Protocols in Human Genetics, 2004, 43, Appendix 1D.	3.5	0
86	PCOLCE deletion and expression analyses in uterine leiomyomata. Cancer Genetics and Cytogenetics, 2002, 137, 133-137.	1.0	18
87	Dysregulation ofHMGIC in a uterine lipoleiomyoma with a complex rearrangement including chromosomes 7, 12, and 14. , 2000, 27, 209-215.		28
88	Genetics of uterine leiomyomata. Genes Chromosomes and Cancer, 2000, 28, 235-245.	1.5	111
89	Identification of female carriers for Duchenne and Becker muscular dystrophies using a FISH-based approach. European Journal of Human Genetics, 2000, 8, 293-298.	1.4	24
90	Genetics of uterine leiomyomata. Genes Chromosomes and Cancer, 2000, 28, 235-245.	1.5	1

#	Article	IF	Citations
91	Expression of HMGIY in Three Uterine Leiomyomata with Complex Rearrangements of Chromosome 6. Cancer Genetics and Cytogenetics, 1999, 114, 9-16.	1.0	48
92	Gene for multiple exostoses (EXT2) maps to 11(p11.2p12) and is deleted in patients with a contiguous gene syndrome. American Journal of Medical Genetics Part A, 1998, 75, 538-540.	2.4	26
93	ORC5L, a New Member of the Human Origin Recognition Complex, Is Deleted in Uterine Leiomyomas and Malignant Myeloid Diseases. Journal of Biological Chemistry, 1998, 273, 27137-27145.	1.6	67
94	Differentially expressed gene products in glioblastoma cells suppressed for tumorigenicity. Journal of NeuroVirology, 1998, 4, 217-226.	1.0	4
95	Simultaneous, Multilocus FISH Analysis for Detection of Microdeletions in the Diagnostic Evaluation of Developmental Delay and Mental Retardation. American Journal of Human Genetics, 1997, 61, 51-59.	2.6	41
96	Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics, 1997, 15, 356-362.	9.4	2,596
97	Suppression of transformed phenotype and tumorigenicity after transfer of chromosome 4 into U251 human glioma cells. Genes Chromosomes and Cancer, 1997, 20, 260-267.	1.5	6